Trends in net survival for patients with stomach cancer in Japan, 2000-14 (CONCORD-3) [0.03%]
日本胃癌患者的净生存率（CONCORD-3）2000～2014年间的趋势分析
Masashi Matsuzaka,Veronica Di Carlo,Melissa Matz et al.
Masashi Matsuzaka et al.
Background: We estimated net survival trends for patients with stomach cancer registered in 16 regional population-based cancer registries in Japan that participated in the CONCORD-3 study. ...
Trends in net survival for 1,834,894 patients with cancer from 16 population-based cancer registries in Japan, 2000-14 (CONCORD-3) [0.03%]
日本人口基于癌症登记处的16个地区2000～2014年1834894例癌症患者的净生存率（CONCORD-3）时间趋势分析
Hiromi Sugiyama,Veronica Di Carlo,Melissa Matz et al.
Hiromi Sugiyama et al.
Background: In 2018, CONCORD-3 updated long-term surveillance of cancer survival trends worldwide. In this monograph, we conducted further analyses and examined trends in net survival using the Japanese data during 2000-1...
Trends in net survival of patients with cutaneous melanoma in Japan, 2000-14 (CONCORD-3) [0.03%]
日本患者黑色素瘤净生存率变化（1998～2014年）(康科德三期研究)
Hiromi Sugiyama,Veronica Di Carlo,Melissa Matz et al.
Hiromi Sugiyama et al.
Background: We assessed survival trends and international comparisons of patients with cutaneous melanoma from Japanese regional population-based cancer registries participating in the CONCORD-3 study. ...
Trends in net survival for patients with brain tumors in Japan, 2000-14 (CONCORD-3) [0.03%]
日本脑肿瘤患者的净生存率（CONCORD-3）：2000至2014年的变化趋势
Laureline Gatellier,Melissa Matz,Hiromi Sugiyama et al.
Laureline Gatellier et al.
Background: Brain tumors are a serious health issue, and survival is an effective indicator of how the healthcare system manages them. We examined net survival trends for patients diagnosed with a primary brain tumor duri...
Reclassification of a BRCA2 variant, c.8487G > a (p.Gln2829Gln) located at 3' end of exon 19, from uncertain significance to likely pathogenic based on splicing alteration: a case report [0.03%]
基于剪接改变将位于外显子19’端的BRCA2变异体c.8487G>a（p.Gln2829Gln）从意义未明重分为很可能致病：病例报告
Ritsuko Sasaki,Hidetaka Eguchi,Sayaka Yoshioka et al.
Ritsuko Sasaki et al.
A BRCA2 germline variant, NM_000059.4: c.8487G > A (p.Gln2829Gln), was identified in a Japanese female with multifocal breast cancer and a notable family history of BRCA2-related cancers. While this synonymous variant was reported as a vari...
Geriatric nutritional risk index predicts 10-year survival in patients with multiple myeloma [0.03%]
老年营养风险指数可预测多发性骨髓瘤患者的十年生存率
Kazuhito Suzuki,Tadahiro Gunji,Riku Nagao et al.
Kazuhito Suzuki et al.
Introduction: Multiple myeloma (MM) remains incurable although a subset of patients achieves survival ≥10 years. However, whether nutritional background predicted long-term survival (LTS), which defined as overall surviv...
Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04) [0.03%]
淋巴结转移是 Pembrolizumab 治疗尿路上皮癌组织学变异型的预后良好因素：YUISHIM 研究-04（一项回顾性多中心研究）
Ichiro Yonese,Fumitaka Koga,Masahiro Toide et al.
Ichiro Yonese et al.
Background: Histological variants (HV) are associated with aggressiveness in urothelial carcinoma (UC). Although immune checkpoint inhibitor (ICI) therapy has improved the prognosis of patients with metastatic UC with HV ...
Age-standardized mortality-to-incidence ratio for thyroid cancer in the world [0.03%]
全球甲状腺癌年龄标准化死亡率发病率比
Kayo Nakata,Tomohiro Matsuda
Kayo Nakata
Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer [0.03%]
全面基因组测序在转移性去势抵抗性前列腺癌患者中的应用体会
Yosuke Yasuda,Soichiro Yoshida,Sadakatsu Ikeda et al.
Yosuke Yasuda et al.
Introduction: Comprehensive genomic profiling (CGP) has expanded treatment options for metastatic castration-resistant prostate cancer (mCRPC); however, real-world data on its clinical utility in Japanese patients remain ...
Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis [0.03%]
恩扎卢胺与阿帕鲁胺治疗转移性激素敏感前列腺癌的多中心倾向性匹配分析
Kazuki Nishimura,Kensuke Hirosuna,Heima Niigawa et al.
Kazuki Nishimura et al.
Background: Androgen receptor signaling inhibitors (ARSIs) such as enzalutamide (Enz) and apalutamide (Apa), in combination with androgen deprivation therapy (ADT), are standard for metastatic hormone-sensitive prostate c...